MX2019003032A - Metodo de reduccion de los efectos laterales asociados con la tiroides. - Google Patents
Metodo de reduccion de los efectos laterales asociados con la tiroides.Info
- Publication number
- MX2019003032A MX2019003032A MX2019003032A MX2019003032A MX2019003032A MX 2019003032 A MX2019003032 A MX 2019003032A MX 2019003032 A MX2019003032 A MX 2019003032A MX 2019003032 A MX2019003032 A MX 2019003032A MX 2019003032 A MX2019003032 A MX 2019003032A
- Authority
- MX
- Mexico
- Prior art keywords
- thyroid
- side effects
- associated side
- receptor agonists
- methods
- Prior art date
Links
- 230000000694 effects Effects 0.000 title abstract 3
- 210000001685 thyroid gland Anatomy 0.000 title abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 229940127535 Thyroid Hormone Receptor Agonists Drugs 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000003532 hypothyroidism Diseases 0.000 abstract 1
- 230000002989 hypothyroidism Effects 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 108090000721 thyroid hormone receptors Proteins 0.000 abstract 1
- 102000004217 thyroid hormone receptors Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Fats And Perfumes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662396025P | 2016-09-16 | 2016-09-16 | |
| US201662396015P | 2016-09-16 | 2016-09-16 | |
| PCT/US2017/051410 WO2018053036A1 (en) | 2016-09-16 | 2017-09-13 | Method of reducing thyroid-associated side effects |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019003032A true MX2019003032A (es) | 2019-09-13 |
Family
ID=61619247
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019003032A MX2019003032A (es) | 2016-09-16 | 2017-09-13 | Metodo de reduccion de los efectos laterales asociados con la tiroides. |
| MX2023000887A MX2023000887A (es) | 2016-09-16 | 2019-03-15 | Metodo de reduccion de los efectos laterales asociados con la tiroides. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023000887A MX2023000887A (es) | 2016-09-16 | 2019-03-15 | Metodo de reduccion de los efectos laterales asociados con la tiroides. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20190255080A1 (enExample) |
| EP (1) | EP3512523A4 (enExample) |
| JP (2) | JP2019531346A (enExample) |
| KR (2) | KR20240074912A (enExample) |
| CN (1) | CN109922812A (enExample) |
| AU (1) | AU2017327383B2 (enExample) |
| CA (1) | CA3037146A1 (enExample) |
| MX (2) | MX2019003032A (enExample) |
| WO (1) | WO2018053036A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11202789B2 (en) | 2016-11-21 | 2021-12-21 | Viking Therapeutics, Inc. | Method of treating glycogen storage disease |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2606499C (en) | 2005-05-26 | 2017-06-13 | Metabasis Therapeutics, Inc. | Thyromimetics for the treatment of fatty liver diseases |
| CA3064940A1 (en) | 2017-06-05 | 2018-12-13 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| AU2019238090B2 (en) | 2018-03-22 | 2024-08-01 | Viking Therapeutics, Inc. | Crystalline forms and methods of producing crystalline forms of a compound |
| US12102646B2 (en) | 2018-12-05 | 2024-10-01 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
| TWI875757B (zh) * | 2019-05-08 | 2025-03-11 | 瑞士商諾華公司 | T1dm和胰島炎治療中使用之抗cd40抗體 |
| RU2728261C2 (ru) * | 2019-05-22 | 2020-07-28 | Ирина Алексеевна Курникова | Способ дифференциальной диагностики йоддефицитного и йодиндуцированного нарушения функции щитовидной железы у лиц, проживающих в регионах с йодным дефицитом |
| CN112457346B (zh) * | 2019-08-19 | 2022-09-06 | 和博医药有限公司 | 一种并环THRβ受体激动剂化合物及其制备方法和用途 |
| AU2020334943A1 (en) * | 2019-08-19 | 2022-03-10 | Hepagene Therapeutics (HK) Limited | Heterocyclic THR-β receptor agonist compound and preparation method and use therefor |
| JP7670687B2 (ja) * | 2020-02-24 | 2025-04-30 | へパジーン セラピューティクス （エイチケイ） リミテッド | 複素環式ＴＨＲ－β受容体アゴニスト化合物ならびにその調製方法および使用 |
| US11752161B2 (en) | 2020-03-27 | 2023-09-12 | Gannex Pharma Co., Ltd. | Pharmaceutical compositions, method of making and method of using thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| MXPA04012497A (es) * | 2002-07-04 | 2005-07-14 | Zealand Pharma As | Glp-1 y metodos para tratar la diabetes. |
| RU2422450C2 (ru) * | 2003-11-19 | 2011-06-27 | Метабазис Терапеутикс, Инк. | Новые фосфорсодержащие тиромиметики |
| CA2606499C (en) * | 2005-05-26 | 2017-06-13 | Metabasis Therapeutics, Inc. | Thyromimetics for the treatment of fatty liver diseases |
| WO2009089093A1 (en) * | 2008-01-04 | 2009-07-16 | Quatrx Pharmaceuticals Company | Thyroid hormone receptor agonists |
| WO2010074992A2 (en) * | 2008-12-22 | 2010-07-01 | Otonomy, Inc. | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders |
| WO2011038207A1 (en) * | 2009-09-25 | 2011-03-31 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyroid hormone receptor agonists and methods of use |
| JP6957601B2 (ja) * | 2016-04-22 | 2021-11-02 | メタベイシス・セラピューティクス・インコーポレイテッド | 甲状腺ホルモン受容体アゴニスト及びその使用 |
| AU2017363206A1 (en) * | 2016-11-21 | 2019-06-13 | Viking Therapeutics, Inc. | Method of treating glycogen storage disease |
-
2017
- 2017-09-13 EP EP17851476.6A patent/EP3512523A4/en active Pending
- 2017-09-13 US US16/333,513 patent/US20190255080A1/en active Pending
- 2017-09-13 CA CA3037146A patent/CA3037146A1/en active Pending
- 2017-09-13 AU AU2017327383A patent/AU2017327383B2/en active Active
- 2017-09-13 MX MX2019003032A patent/MX2019003032A/es unknown
- 2017-09-13 KR KR1020247016178A patent/KR20240074912A/ko active Pending
- 2017-09-13 JP JP2019536463A patent/JP2019531346A/ja active Pending
- 2017-09-13 KR KR1020197010782A patent/KR20190060786A/ko not_active Ceased
- 2017-09-13 CN CN201780068418.8A patent/CN109922812A/zh active Pending
- 2017-09-13 WO PCT/US2017/051410 patent/WO2018053036A1/en not_active Ceased
-
2019
- 2019-03-15 MX MX2023000887A patent/MX2023000887A/es unknown
-
2022
- 2022-09-16 JP JP2022148311A patent/JP7656574B2/ja active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11202789B2 (en) | 2016-11-21 | 2021-12-21 | Viking Therapeutics, Inc. | Method of treating glycogen storage disease |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3512523A1 (en) | 2019-07-24 |
| EP3512523A4 (en) | 2020-05-06 |
| NZ751857A (en) | 2024-05-31 |
| JP2022174261A (ja) | 2022-11-22 |
| WO2018053036A1 (en) | 2018-03-22 |
| AU2017327383A1 (en) | 2019-04-11 |
| CA3037146A1 (en) | 2018-03-22 |
| US20190255080A1 (en) | 2019-08-22 |
| BR112019005039A2 (pt) | 2019-06-25 |
| KR20240074912A (ko) | 2024-05-28 |
| JP7656574B2 (ja) | 2025-04-03 |
| KR20190060786A (ko) | 2019-06-03 |
| JP2019531346A (ja) | 2019-10-31 |
| CN109922812A (zh) | 2019-06-21 |
| MX2023000887A (es) | 2023-02-22 |
| AU2017327383B2 (en) | 2023-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023000887A (es) | Metodo de reduccion de los efectos laterales asociados con la tiroides. | |
| MX2021006575A (es) | Composiciones y metodos para el tratamiento de trastornos del higado. | |
| PH12020551025A1 (en) | Incretin analogs and uses thereof | |
| PH12020551024A1 (en) | Incretin analogs and uses thereof | |
| PH12019501131A1 (en) | Composition for treating hyperlipidemia comprising oxytomodulin derivative | |
| NZ729678A (en) | Methods of treating non-alcoholic steatohepatitis using ask1 inhibitor in combination with a fxr agonist | |
| TN2017000148A1 (en) | Co-agonists of the glucagon and glp-1 receptors | |
| WO2018231905A8 (en) | Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia | |
| BR112014006220A2 (pt) | composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica | |
| GB2503852A (en) | Compounds for the treatment of neuropsychiatric disorders | |
| PH12019502330A1 (en) | Pharmaceutical compositions and methods of treating cardiovascular diseases | |
| SG10201808055QA (en) | Compositions and methods for reducing major adverse cardiovascular events | |
| BR112019023820A2 (pt) | moduladores duplos de receptor de farnesoide x e epóxido hidrolas solúvel | |
| MX374612B (es) | Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp. | |
| MX2015015036A (es) | Metodos para mejorar los perfiles de lipidos utilizando atrasentan. | |
| MX2018008299A (es) | Metodos para administrar hepcidina. | |
| BR112015022513A2 (pt) | produto e método para tratamento de diarreia | |
| EP4234536A3 (en) | Amino-aryl-benzamide compounds and methods of use thereof | |
| BR112014003545A2 (pt) | método para transformar uma refeição | |
| PH12014500843B1 (en) | Composition and method of phytonutrients for metabolic programming effects | |
| WO2020159321A3 (ko) | 영장류를 대상으로 한 미세투석 및 다종 신경전달물질 동시 분석을 이용한 신경정신질환 치료제 약효 평가방법 | |
| EA201990563A1 (ru) | Способ уменьшения побочных эффектов, ассоциированных с щитовидной железой | |
| MY206033A (en) | Enzyme composition | |
| MX2019007236A (es) | Metodos de administracion de hepcidina. | |
| EP2992885A3 (en) | Method for inhibiting a liver disease |